<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01111591</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBH-GS-HBP2</org_study_id>
    <secondary_id>B-0712-052-006 (local IRB)</secondary_id>
    <nct_id>NCT01111591</nct_id>
  </id_info>
  <brief_title>Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer</brief_title>
  <official_title>Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; CelebrexÂ®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In extrahepatic bile duct cancer and pancreatic cancer, we will treat postoperatively with
      COX2 inhibitor and assess survival rate and recurrent rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients : total 220 patients

        -  Extrahepatic bile duct cancer : 55 patients for administration of COX2 55 patients for
           control group

        -  Pancreas cancer : 55 patients for administration of COX2 55 patients for control group

      Indication

        -  After operation of extrahepatic bile duct cancer or pancreas cancer

        -  Age : 19 - 70 years old

        -  The patients who agree to consent sheet.

      Contraindication

        -  Impossible of administration due to severe postoperative morbidities (bleeding, bowel
           obstruction, pancreatic fistula, biliary fistula)

        -  Preexisting heart disease: Ischemic heart disease, Heart failure. Severe uncontrolled
           hypertension (systolic BP&gt;160)

        -  Renal insufficiency: CCR &lt; 50 or serum creatinin &gt;3.0

        -  Hepatic insufficiency: Liver cirrhosis or active hepatitis

        -  Preexisting allergic reaction history for NSAIDs or Sulfonamide

        -  Current drug intake: Warfarin. Lithium, Fluconazole, Aspirin, Celecoxib

        -  Preexisting Asthma. Especially aspirin-sensitive asthma.

        -  Contraindications to aspirin, clopidogrel or celecoxib

        -  The patients who refuse trial

        -  The patients who has Psychogenic problem

      Allocation

        -  We will allocate patients randomly, to administration group or control group

      Methods

        -  From postoperative third day, administration will be started

        -  celecoxib 200mg bid for 6 months for administration group

        -  Follow up and assess recurrence rate and survival rate
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short term outcome</measure>
    <time_frame>2 years</time_frame>
    <description>Recurrent rate and survival rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term outcome</measure>
    <time_frame>4 years</time_frame>
    <description>Recurrent rate and survival rate</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Bile Duct Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>2. Bile duct cancer - control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Bile duct cancer patients do not administration of COX inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Pancreas cancer - experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pancreas cancer patients take a COX2 inhibitor 200mg every 12hours for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4. Pancreas cancer - control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Pancreas cancer patients do not administration of COX inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bile duct cancer - experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bile duct cancer patients take a COX2 inhibitor 200mg every 12hours for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cox2 inhibitor (Celecoxib)</intervention_name>
    <description>From postoperative third day, administration will be started celecoxib 200mg bid for 6 months for administration group.</description>
    <arm_group_label>3. Pancreas cancer - experimental</arm_group_label>
    <arm_group_label>Bile duct cancer - experimental</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients who underwent operation for extrahepatic bile duct cancer or pancreas
             cancer

          -  Between 19 and 70 years old

          -  Agreed to consent sheet

        Exclusion Criteria:

          -  The patients cannot administration of drug due to severe postoperative morbidities.

          -  Preexisting heart disease: Ischemic heart disease, Heart failure. Severe uncontrolled
             hypertension (systolic BP&gt;160)

          -  Renal insufficiency: CCR &lt; 50 or serum creatinin &gt;3.0

          -  Hepatic insufficiency: Liver cirrhosis or active hepatitis

          -  Preexisting allergic reaction history for NSAIDs or Sulfonamide

          -  Current drug intake: Warfarin. Lithium, Fluconazole, Aspirin, Celecoxib

          -  Preexisting Asthma. Especially aspirin-sensitive asthma.

          -  Contraindications to aspirin, clopidogrel or celecoxib

          -  When patients refused

          -  Patients has psychological problem
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ho-Seong Han, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>General surgery department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ho-Seong Han</name>
      <address>
        <city>Seonnam City</city>
        <state>Gyeon gi do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Koo BK, Kim YS, Park KW, Yang HM, Kwon DA, Chung JW, Hahn JY, Lee HY, Park JS, Kang HJ, Cho YS, Youn TJ, Chung WY, Chae IH, Choi DJ, Oh BH, Park YB, Kim HS. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. Lancet. 2007 Aug 18;370(9587):567-74. Erratum in: Lancet. 2007 Sep 14;370(9590):828.</citation>
    <PMID>17707751</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2009</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Ho-Seong Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cyclooxygenase-2 inhibitor (Celecoxib)</keyword>
  <keyword>Extrahepatic bile duct cancer</keyword>
  <keyword>Pancreas cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancrelipase</mesh_term>
    <mesh_term>Pancreatin</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

